📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The FDA risk-management assessment and REMS (Risk Evaluation and Mitigation Strategy) analysis — whether extra safety controls beyond labeling are needed.
Why it exists. For some drugs the FDA requires a REMS: measures such as a Medication Guide, communication plans, or controlled distribution to ensure benefits outweigh risks. This document assesses whether GLPI-103's risk profile requires one.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. FDAAA §505-1 (REMS) · 21 CFR 208 (Medication Guide) · 21 CFR 201.57 (PLR)
| Field | Value |
|---|---|
| Document ID | RMP-US |
| Version | 2.0 (full) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Region | FDA (US) |
| Standard | FDAAA §505-1 (REMS) · 21 CFR 208 (Medication Guide) · 21 CFR 201.57 (PLR) |
| Confidentiality | Confidential |
No comments yet. Be the first to say something!
Uses the master safety specification from the EU-RMP (RMP-EU Part II). US risk management emphasizes labeling and the Medication Guide, consistent with the GLP-1 receptor agonist class.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Pharmacovigilance / Regulatory | Initial assessment |
| 2.0 | 2026-06-29 | Pharmacovigilance / Regulatory | Full — REMS framework analysis, labeling detail, PV plan |
Important identified risks: gastrointestinal adverse events; hypoglycaemia (with insulin secretagogues). Important potential risks: acute pancreatitis; thyroid C-cell tumours (MTC/MEN2); cardiovascular/heart-rate effects (APJ-mediated); immunogenicity. Missing information: pregnancy/lactation; paediatric use; severe renal/hepatic impairment; long-term and cardiovascular-outcomes safety.
The determination of whether a REMS is required weighs: the seriousness of known/potential adverse events; the expected benefit; the duration of treatment; the seriousness of the disease; and the size of the treated population. Applying this framework:
Conclusion: the benefits of routine risk management outweigh the incremental value of REMS elements; a REMS is not proposed. This determination will be re-evaluated if post-marketing data indicate a new or disproportionate risk not adequately mitigated by labeling.
A patient Medication Guide is dispensed, addressing: recognition of symptoms of thyroid tumours and acute pancreatitis; management of gastrointestinal effects through titration; and hypoglycaemia precautions when used with other glucose-lowering medicines.
Routine pharmacovigilance (FAERS signal detection; 15-day expedited and periodic safety reporting); targeted follow-up for pancreatitis and MTC; a pregnancy exposure registry; and a post-marketing long-term/cardiovascular safety study (aligned with the EU PASS, RMP-EU Part III).
GLPI-103's risks are adequately managed by routine, labeling-based risk minimization (including a class boxed warning and a Medication Guide) together with routine and post-marketing pharmacovigilance; no REMS is warranted at approval.